News
Bladder cancer: causes and limitations of the VOLGA study
Sabine Schneider ·
The VOLGA study involved people with muscle-invasive bladder cancer for whom cisplatin-based chemotherapy was unsuitable or who refused it.
The data do not apply across the board to all men and women who develop bladder cancer, nor do they apply to all stages of the disease. The depth of tumour invasion, its spread and the patient’s physical condition remain decisive factors in treatment.

Key points at a glance
- Limitations of the study: The two VOLGA groups receiving durvalumab combinations were not directly compared with one another, so it is not possible to determine which combination is superior.
- Limited generalisability: The study involved people with muscle-invasive bladder cancer who were unable to receive or refused cisplatin.
- Possible warning sign: Blood in the urine can be a sign of bladder cancer and may occur without pain.
- Key diagnostic test: Cystoscopy is the key diagnostic test for bladder cancer.
- Treatment based on depth of invasion: Non-muscle-invasive bladder cancer can be removed via the urethra, whilst in the case of a non-metastatic muscle-invasive tumour, the entire bladder is often removed.
What are the symptoms and risk factors?
Bladder cancer may present with blood in the urine. This discolouration of the urine may occur without pain. Other possible symptoms include a frequent urge to urinate and discomfort when passing urine. A bladder infection or other conditions can also cause such symptoms.
Possible early signs of bladder cancer include:
- Blood in the urine: The blood may be visible or only detectable during a urine test.
- Frequent urge to urinate: Those affected need to urinate more frequently.
- Pain or a burning sensation: These symptoms occur when passing urine.
- Changes in bladder function: New problems with emptying the bladder persist.
Smoking can increase the risk of bladder cancer and is the most significant known risk factor.
How is the diagnosis made if bladder cancer is suspected?
The most important examination is cystoscopy. It is carried out by a urologist.
This allows the mucous membrane to be viewed directly. Abnormal tissue can be removed and examined in more detail.
A urine test can detect blood and abnormal cells. The ureters between the kidneys and the bladder can also be examined.
After the bladder tissue has been removed, the laboratory checks whether the cancer cells are confined to the lining or have already spread into the muscle layer. This information is essential for the diagnosis, staging and further treatment.
To assess the extent of the disease, magnetic resonance imaging (MRI) can be used to supplement the tissue examination. MRI provides cross-sectional images of the bladder wall and the surrounding urinary tract.
What determines the prognosis?
The depth of tumour invasion determines the prognosis and the choice of treatment. Non-muscle-invasive bladder cancer is confined to the mucous membrane. In muscle-invasive bladder cancer, the tumour has invaded the muscle layer of the bladder wall.
Very superficial bladder cancer generally has a good chance of being cured. In the case of advanced tumours, the prognosis becomes less favourable as the depth of invasion and spread increase. Another important factor is the extent to which the cancer cells differ from normal cells.
A tumour that is initially non-muscle-invasive may progress despite treatment and later reach the muscle layer. The outcome of this determines whether the bladder can be preserved.
Classification according to depth of invasion and spread also forms the basis for how bladder cancer is treated. Bladder cancer, bladder carcinoma and urinary bladder carcinoma are terms used to describe this malignant disease of the bladder.
What is the standard treatment to date?
The treatment of bladder cancer depends primarily on the depth of invasion, the extent of the tumour and the type of tumour cells. Consequently, different treatment options are available for superficial tumours than for muscle-invasive cancer.
| Treatments | Who is it suitable for? | What happens? |
|---|---|---|
| Transurethral resection | Non-muscle-invasive bladder cancer | The tumour is removed via the urethra using an electric loop. The procedure is called transurethral resection of the bladder, or TUR-B for short. |
| Local therapy | Non-muscle-invasive bladder cancer | Medicines are administered directly into the bladder. Bacillus Calmette-Guérin (BCG) may be used for immunotherapy. |
| Radical cystectomy | Commonly used for non-metastatic muscle-invasive bladder cancer | In this operation, the entire bladder is removed. |
| Bladder-preserving therapy | Selected patients with muscle-invasive bladder cancer | Following tumour removal, a combination of chemotherapy and radiotherapy is administered. |
A cystectomy may also be necessary in cases of non-muscle-invasive bladder cancer. It is considered when there is a very high risk of recurrence. This applies, for example, in cases of particularly aggressive tumour growth.
Following this procedure, a urinary diversion is required. One option is a so-called neobladder made from bowel tissue. The type of urinary diversion that is suitable depends on the nature of the disease and the patient’s physical condition.
How were the VOLGA groups compared?
The study comprised two groups receiving durvalumab combinations.
The two VOLGA groups receiving durvalumab combinations were not directly compared with one another. It is therefore not possible to conclude from the study which combination is better.
How should the limitations of the study be understood?
A percentage figure relating to a study endpoint does not automatically correspond to the personal risk reduction for an individual patient. The percentage refers to the patient groups studied and must not be interpreted as an individual prognosis.
The term ‘without chemotherapy’ also needs to be contextualised. Side effects and an individual’s ability to tolerate treatment remain relevant to the clinician’s decision.
The study does not demonstrate a general benefit for all people with bladder cancer, as only a limited group of patients was studied. Its findings do not apply across the board to non-muscle-invasive tumours, nor to all patients with muscle-invasive disease. Nor can the results be applied across the board to advanced bladder cancer with metastases in lymph nodes or other organs.
What happens after treatment?
In the case of non-muscle-invasive bladder cancer, the tumour recurs in 5 to 7 out of 10 patients or does not respond to treatment; this does not indicate an individual risk of recurrence.
Even a superficial tumour can later invade the muscle layer.
If the bladder has been preserved, cystoscopy can be used again. Following a cystectomy, follow-up care also takes into account urinary diversion and the course of the disease. Any new symptoms that arise between appointments should be investigated by a doctor.
Frequently asked questions about bladder cancer and the VOLGA study
Is blood in the urine a warning sign even if there is no pain?
Yes, blood in the urine can occur without pain in cases of bladder cancer. However, there are also other possible causes. The source of the bleeding can only be determined through medical examinations.
Why is a cystoscopy important?
A cystoscopy is the most important examination for diagnosing bladder cancer.
What does ‘muscle-invasive bladder cancer’ mean?
‘Muscle-invasive’ means that the cancer has grown into the muscle layer of the bladder wall. This finding influences the prognosis and the choice of treatment.
For which women and men are the study results relevant?
The VOLGA results relate to selected people with muscle-invasive bladder cancer. Cisplatin-based chemotherapy was unsuitable for the participants, or they had refused it.
What does ‘bladder carcinoma’ mean?
Bladder cancer and carcinoma of the bladder refer to the same type of cancer. On their own, these terms do not indicate how deeply the abnormal tissue has penetrated the bladder wall.
Share this article
Verified expertise
Recommended specialists
9 specialists
9 results

GASSMANN MEDICAL
Münstertal (Black Forest)



Dr Wilfried Stücker
Cologne




Prof. Dr. med. Marko Brock
Recklinghausen

News
Read next
- News
Knee replacement: Just how precisely does an implant actually fit these days?
Nov 16, 2026
Knee replacement: Just how precisely does an implant actually fit these days?
Read more - News
Hyperthermia in cancer treatment: What heat therapy can achieve
Nov 13, 2026
Hyperthermia in cancer treatment: What heat therapy can achieve
Read more - News
Hallux valgus: What really helps with a crooked big toe
Nov 11, 2026
Hallux valgus: What really helps with a crooked big toe
Read more



